FDA Brief

Warning letters Drugs

FDA warning letter to

Evi Labs LLC

High riskIssued May 14, 2025Posted Jun 3, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Evi Labs over OTC drug manufacturing failures, including an antiperspirant lot above the aluminum chlorohydrate limit.

What happened

FDA inspected Evi Labs' drug manufacturing facility in Medley, Florida, from January 9 to 15, 2025. FDA found violations of current good manufacturing practice (CGMP), including release of OTC drug batches without adequate identity and strength testing and microbiological specifications above USP guidance. One tested antiperspirant lot, 291023, had aluminum chlorohydrate above 25%, which is not permitted under the OTC antiperspirant monograph.

What FDA found

  1. Released OTC drug batches without adequate identity and strength testing before release; lot 291023 of Zermat Kiwi Perfumado had aluminum chlorohydrate above 25%, above the OTC monograph limit.

    21 CFR 211.165(a)
  2. Set microbiological specifications higher than USP guidance and released antiperspirant drug products that exceeded appropriate microbiological quality.

    21 CFR 211.160(b)
  3. Failed to adequately validate and maintain the water system, which had a dead leg, did not continuously circulate, and lacked validated sanitization and routine monitoring.

    21 CFR 211.100(a)
  4. Failed to validate manufacturing processes and to adequately document and control critical process steps and qualify equipment such as scales.

    21 CFR 211.100(a)
  5. The quality unit did not effectively oversee quality, did not ensure API quality, investigate discrepancies, control computer systems, or establish stability testing, and did not reject failing or untested topical products.

    21 CFR 211.22(a)

What FDA wants

FDA tells Evi Labs to correct the violations promptly and respond in writing within 15 working days with corrective actions, including testing retained samples, assessing risks to distributed products, notifying customers and recalling products if needed, and hiring a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC drugs from this contract manufacturer
  • distributors and retailers selling Zermat antiperspirants
  • consumers using the affected antiperspirants or oral suspension

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk